INTACEPT PRICE IN INDIA REGISTRATION
INTACEPT PRICE IN INDIA FREE

Intas Pharmaceuticals Limited is a leading vertically integrated Indian pharmaceutical company committed on delivering affordable and innovative pharmaceutical solutions.

INTACEPT PRICE IN INDIA REGISTRATION

In addition, Intas is also the only company from India to have two of its biosimilars, filgrastim and peg-filgrastim filed for registration in the US. INTACEPT is also produced in the same manufacturing facilities as its other biosimilars. The company's biosimilar manufacturing facilities have been approved by global regulatory agencies such as EMA, ANVISA, WHO and others. Its first biosimilar for global markets, Accofil (filgratsim) was launched in Europe in January of this year. Intas is also the only company from India to have registered and launched a biosimilar in the highly regulated European market. The company continues to have one of the richest pipeline of future products, thereby ensuring cost effective biosimilar alternates to imported and expensive biologic therapies. With the launch of INTACEPT, the company now has nine biosimilar products in the market, including one monoclonal antibody MABTAS (rituximab), the largest indigenously development portfolio of biosimilar products. Intas is one of the pioneers and market leaders of biosimilars in India, having launched its first product in the domestic market in 2004. Through INTACEPT, we are able to reduce the cost of treatment for patients to about half of the imported Enbrel®.' INTACEPT is a further validation of our world-class R&D and manufacturing capabilities that bring global healthcare standards to Indian patients at a lower cost. Binish Chudgar, Vice-Chairman of the Company, said, 'Etanercept is a fusion protein that is difficult to develop. Etanercept is indicated for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Plaque Psoriasis, all debilitating autoimmune diseases.

INTACEPT PRICE IN INDIA FREE

INTACEPT, Intas' etanercept, has been launched in two strengths, 25mg in 0.5 ml and 50 mg in 1.0 ml preservative free solution, in easy to use pre-filled syringes. Please click here for detailed T&C.Intas Pharmaceuticals today announced that they have launched INTACEPT, the first biosimilar to Amgen's Enbrel® (etanercept). You hereby agree that you shall not make any health or medical-related decision based in whole or in part on anything contained in the Site. We highly recommend that you consult your registered medical practitioner for all queries or doubts related to your medical condition.

The absence of any information or warning to any medicine shall not be considered and assumed as an implied assurance. Nothing contained on this page is intended to create a doctor-patient relationship, replace or be a substitute for a registered medical practitioner's medical treatment/advice or consultation.

You should not use the information provided herein to diagnose, prevent, or cure a health problem. This information is solely intended to provide a general overview on the product and must be used for informational purposes only. The information provided herein is supplied to the best of our abilities to make it accurate and reliable as it is published after a review by a team of professionals.

Intacept price in india